ArticleAnnals of oncology : official journal of the European Society for Medical Oncology2021

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

G Saturno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.